Skip to main content

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

Feedback
Newsletter
RSS
Twitter

User Top Menu

Welcome, guest
Log In
Join
Why Join?

Search form

Search

About Us
- Overview
- Who We Are
- Contact
- Fan Mail
- How to Cite
News & Future Directions
Papers
Forums
- Discussions
- Webinars
Professional Resources
Research Resources
Click Here to Support MSDF

You are here

Most Viewed

Laquinimod CHMP/EMA opinion
Dimethyl fumarate (Tecfidera) for multiple sclerosis.
"Putting One Foot in Front of the Other": A Qualitative Study of Emotional Experiences and Help-Seeking in Women with Multiple Sclerosis.
Cerebrospinal Fluid Flow Dynamics in Multiple Sclerosis Patients through Phase Contrast Magnetic Resonance Imaging.
Multiple sclerosis.
Optical coherence tomography in multiple sclerosis.
Analysis of the Paired TCR α- and β-chains of Single Human T Cells.
Using a highly abbreviated California Verbal Learning Test-II to detect verbal memory deficits.
Mobile phones and multiple sclerosis - a nationwide cohort study in denmark.
Relapses in patients treated with fingolimod after previous exposure to natalizumab.
Disease Suppression Persists With Ozanimod at 72 Weeks in MS
Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis.
Paroxysmal Hypothermia in Two Patients with Multiple Sclerosis.
Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis (EAE) Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge.
A touch of MS: Therapeutic mislabeling.
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
FDA approves injectable drug to treat opioid-dependent patients
Natalizumab to fingolimod washout in patients at risk of PML: When good intentions yield bad outcomes.
Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.
Segway use in individuals with multiple sclerosis.
[Sexuality of men with neurologic disorders].
The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials.
Significance of Virchow-Robin Spaces in Patients Newly Diagnosed with Multiple Sclerosis: A Case-Control Study in an Arab Population.
The next generation of exoskeletons: lighter, cheaper devices are in the works.
About Tysabri

Pages

« first
‹ previous
…
186
187
188
189
190
191
192
193
194
…
next ›
last »

MSDF Footer

Copyright © 2014 MGH and ACP

Privacy
Terms of Use
How to Cite
FAQ/Help
Site Map
Support Us
Feedback
Image Credits

All site content, except where otherwise noted, is licensed under a Creative Commons BY license. Please let us know where and how you use MSDF material.

Content By

Software By